QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced an agreement with Eli Lilly and Company (NYSE: LLY) to develop…
Super UserNovember 20, 2013
Paul Silber had some unexpected advice from a venture capitalist for the entrepreneurs who crowded a conference room at the…
Super UserNovember 18, 2013
We’ve all done it. You throw your clothes in a bag and head to the airport. Sixteen hours later, you’re…
Super UserNovember 18, 2013
Much has been written about the pharmaceutical industry’s R&D-productivity challenge during the past decade: the decline in new-drug approvals has…
Super UserNovember 18, 2013
GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been approved in Europe to treat both asthma and chronic obstructive…
Super UserNovember 18, 2013
QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced an agreement with Eli Lilly and Company (NYSE: LLY) to develop…
Super UserNovember 18, 2013
We’ve heard a lot this year about the IPO boom for biotech companies. Even after a few high-profile blowups (Ariad,…
Super UserNovember 18, 2013
AstraZeneca (AZ) has strengthened its research team by appointing leading academic Dr Yong-Jun Liu as head of research at its…
Super UserNovember 18, 2013
A Cambridge company developing new drugs focused around DNA damage and genetically defined cancers has attracted investment from another pharma…
Super UserNovember 18, 2013